Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer

Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00816452

Acronym

InoPro

Enrollment

180

Registered

2009-01-01

Start date

2009-01-31

Completion date

2010-07-31

Last updated

2010-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Prostate Cancer

Keywords

Osteoporosis, Prostate Cancer, Osteoporosis in male with Prostate Cancer

Brief summary

Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician. Primary Objective: To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis. Secondary objectives: To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists. To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Man with Prostate Cancer * Men ≥70 years old or ≥60 years old treated by LH-RH agonist for at least 2 years or Man who was diagnosed in the past with Osteopenia/osteoporosis * Osteopenia/osteoporosis proven by bone density test.

Exclusion criteria

* Creatinine clearance \< 30ml/min * Hypercalcemia * Actual treatment by Bisphosphonate or steroids * Hypersensibility to Bisphosphonate or any contraindication to its use. * Metastatic prostate Cancer * Patients not suitable for compliance. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame
To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis.	6 months

Secondary

Measure	Time frame
To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists.	6 months
To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics	6 months
To evaluate incidence of osteopenia/osteoporosis in this study population.	6 months

Countries

Israel

Outcome results